Compare AbbVie Inc (ABBV) vs Ferrari NV (RACE) Price & Performance

AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.

The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.

Ferrari (RACE) trades at $386.99, up 0.52% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow. Recent news highlights the company's ongoing share buyback program and strategic moves like the new V12 model and EV developments. Analyst sentiment remains positive with a $467.50 consensus target.

The outlook is favorable given Ferrari's pricing power and hybrid sales growth, but risks include EV market reception and economic sensitivity. Wall Street's strong buy consensus (72% buy ratings) supports upside potential, though high valuation multiples warrant caution amid competitive and macroeconomic pressures.